Lung cancer is responsible for most of the deaths (due to cancer) across the globe. With just one drug slated to be launched by 2014 – Talactoferrin by Agennix AG, for patients with advanced lung cancer; having failed both chemotherapy and treatments with epidermal growth factor receptor (EFGR) - Tyrosine kinase inhibitor (TKI). Lung cancer is still an area with high unmet need for early diagnosis and limited treatment options in the advanced stages of lung cancer.
The prevalence of diabetes is increasing globally with the increase in life expectancy and rising incidence of obesity. Brazil’s diabetes drugs market is showing a double digit growth rate; while the Russian insulin market is also expected to witness significant growth with an estimated over 20 million patients in the region requiring diabetes treatment by 2025. India and China have the highest number of diabetics in the world – China alone is expected to have more than 71 million diabetic patients by 2025; and the similarly huge patient-base in India has already attracted a number of pharmaceutical companies such as Eli Lilly and Novo Nordisk. These companies are offering easy-to-use insulin versions to grab the market share in the Indian market for diabetes drugs. Thus, diabetes drugs market in BRIC economies is expected to have significant growth opportunities in the years to come.
The increase in public awareness and government initiatives, as a consequence of scare from pandemic flu has resulted in the drastic rise in demand for the Influenza Vaccines. This transient boost in demand of seasonal influenza vaccines is an impact of prevailing H1N1 pandemic, due to apprehension and lack of clarity among the general public. The emerging technologies in production are going to give a new face to the market dynamics of this market. The upcoming vaccines and drugs by various players in the market such as Novartis’ Optaflu and ProteinSciences’ FluBlock, along with the emerging technologies in production are going to give a new face to the market dynamics of this market.
The report sizes the market for the diagnosis and therapeutic technologies for the auto immune diseases. It also tracks the advances in the technologies along with the profiles and strategies of the key players in this market. The report highlights the new approaches being pursued in this market.